SERVATRIX BIOMED
Contact information
- Drug development
- Drug discovery
- Inflammatory diseases
- Digestive system and hepatology
- Central nervous system
Servatrix Biomed S.L. is a biotechnology spin-off from the Autonomous University of Madrid. Since its establishment, it has positioned in the market as a developer of innovative solutions and therapies for chronic diseases, with its main value proposition being its ability to generate new drugs that activate the NRF2 transcription factor (a master regulator of cytoprotective responses against oxidative, inflammatory, or metabolic stress), leveraging its privileged position within the framework of this technological transfer.
SERVATRIX provides highly innovative strategies for the treatment of a highly prevalent disease worldwide: non-alcoholic steatohepatitis (NASH), also known as steatohepatitis associated with metabolic dysfunction, MASH, and its prohression towards liver fibrosis and cirrhosis.
Pharma, CROs, Consortiums, Consultants & Other startups in related fields.
Biotech Sanitaria
| Product / Service | Type | Therapeutic area | Development phase |
|---|---|---|---|
| Terapias avanzadas para enfermedades hepaticas. NASH | Biodrugs/ Drugs | Sistema digestivo y hepatología | R&D |